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18 Oral Presentationsas a source of Adv andCMVantigens. CB-derived dendritic cells were
transduced with the Ad5f35pp65 vector to stimulate virus-specific
CTL followed by stimulation with autologous CB-derived lympho-
blastoid cells (LCL) transducedwith the samevector.After3weeks ex-
pansion, 9 CTL lines contained a mean of 83% (range 64–94%)
CD81 and 27% (range 12–40%) CD41 T-cells. Flow cytometric
analysis of memory markers revealed a predominance of CD45RA-
CD62L- T-cells (69618%; range 25–93) with a smaller population
of CD45RA- CD62L1 T-cells (1065%; range 1–23). Evaluable
CB CTL lines showed specific cytolytic activity in 51Cr release assays
against CMV and Adv targets. IFNg ELISPOT assays on CTL lines
demonstrated a mean of 209 (range 45–694) and 74 (range 0–188)
spot-forming cells/1  105 T-cells following incubation with CMV-
pp65 and Adv-hexon/penton peptides respectively. No significant re-
sponse to irrelevant peptides was demonstrated. The expanded CB
CTL had a broad Vb repertoire and were specific for multiple viral
epitopes. In addition, the virus-specific T cells were shown to be ex-
panded only from T-cells with a naive phenotype (CD45RA1/
CCR71). These results demonstrate that, despite the generally naive
nature of CB lymphocytes, bi-virus-specific responses can be ex-
panded in vitro andcouldpotentially beused clinically inCBTpatients
who develop infectious complications prior to immune reconstitution.41
THE ‘‘MARROWMINER’’, A NOVEL, MINIMALLY INVASIVE DEVICE FOR
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Introduction: Bone marrow (BM) is the traditional graft source in
hematopoietic stem cell transplantation. An increasing body of work
suggests thatuseofBMgraftsmayshow long-termadvantagesovermo-
bilized PBSC in some alloegeneic settings, resulting in less cGVHD,
morbidity and improved survival. Traditional O.R. based BM harvest
methods are crude, labor and resource intensive, generally requiring
100–2001 serial small volume needle aspirates, and result in grafts
highly diluted by peripheral blood. Improved BM harvest methods
are needed. The ‘‘MarrowMiner’’ (MM), is a novel, FDA cleared and
CE-Marked device developed for the minimally invasive harvest of
BM to enable the rapid, convenient, outpatient harvest of large quanti-
ties of BM via a single marrow entry site, under local anesthesia.
Methods:TheMARVELOUS (MARrowMinerVErsus standard
ILeac bOne marrow pUncture and aSpiration) trial was designed to
compare harvest of the MM with standard serial-puncture needle
harvest in the same patient. 21 patients undergoing autologous mar-
row derived cell therapy were enrolled, and had BM harvested under
local anesthesia from their anterior (10) or posterior (11) ileac by the
MM, followed by serial marrow aspirates with standard 6-hole
harvest needles from the opposite hip. Cell viability, counts,
CD341, ALDH1, T cell, and MSC populations were compared.
Results: The MM successfully harvested large volumes (up to
300ml) of marrow under local anesthesia without any complications.Average intrapatient ratio of cell counts from marrow ob-
tained by MarrowMiner and by standard harvest aspirate
method
Total
Nucleated
Cell Count /
ml % CD341 % CD31
% MSC
phenotype
%
ALDH1
Mean ratio:
Marrow
Miner counts /
Standard
Harvest
counts
1.98 1.22 0.78 7.96 3.56
*Results from initial 10 of 21 patients with full flow cytometry data avail-
able at time of submission.MM harvest samples had a greater average TNC count / ml
compared to standard marrow harvest in the same patient (1.98
greater TNC (0.87–3.3 6 p\.05). Viability was equivalent at
(.99%). In addition to higher TNC/ml, higher levels (mean 3.56
fold) of % ALDH1, CD341, phenotypic MSC (7 fold) and CFU
were obtained by MM while % CD31 was lower.
Conclusions: The novel MarrowMiner system demonstrated
safety and efficacy in clinical use, while harvesting more CD341
cells per ml via single iliac entry compared to standard harvest
methods. This suggests the MM may enable improved clinical har-
vests in a more rapid and minimally invasive manner, improving
donor safety and convenience while obtaining a richer marrow prod-
uct, requiring less total volume and with less peripheral blood con-
tamination. Such a system, facilitating convenient, on demand
stem cell collection and improved safety and convenience for the do-
nor may have significant application for BMT and other marrow
based cell therapies.42
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In utero stem cells transplantation (IUSCT) presents immunolog-
ical and therapeutic potentials advantages over postnatal stem cells
transplantation (SCT).The peculiar, immunological status of the fe-
tus allows donor-specific tolerance and can eliminate the require-
ment of pharmacological immunosuppression. Furthermore
IUSCT potentially prevents clinical manifestations that can start at
this stage of development and, indeed, the small size of the foetus al-
lows a much higher relative doses of stem cells, favouring successful
engraftment. Mesenchymal stem cells (MSCs) are multipotent stem
cells able to differentiate into diverse lineages, including osteocytes,
chondrocytes, adipocytes. MSCs have a peculiar homing-capacity,
when injected in animal models, colonizing irradiated mesoderm-
derived tissues, ischemic myocardium, liver and brain.On the ratio-
nal of their trafficking capacity to injured tissues, clinical trials have
been started with the employment of MSCs in the treatment of met-
abolic diseases like Hurler syndrome and metachromatic leukodys-
trophy, or Osteogenesis Imperfecta (OI). Our centre performed
seven in utero transplants in foetuses affected by SCID and Osteo-
genesis Imperfecta with improvement of clinical presentation in
most cases and low procedure related morbility. SCID fetuses have
been transplanted with haematopoietic CD341 stem cells, in three
casesMSCwere coinjected (2 OI;1 SCID).With the aim of realizing
a prenatal gene therapy protocol, our group has successfully isolated,
expanded and characterized human multi-potent MSCs from 11
samples of second-trimester amniotic fluid. These cells result to be
expandable in specific conditions and to express mesenchymal
markers, above all between te 3rd and the 4th week of colture.Telo-
merase activity and telomers length have been evaluated demonstrat-
ing an absent spontaneous transformation tendency. Transduction
efficacy of Amniotic Fluid Mesenchymal Stem Cells (AFMSC) has
been assessed using a SIN HIV-1–based lentiviral vector. This vec-
tor encloses SFFV-U3promoter and eGFP.We found a transduction
efficiency of 60%. We suggest that AFMSCs, with their ready
expandability, ability to differentiate into multiple lineages and
high transduction efficiency, may be good target for neonatal regen-
erative surgery and for in utero gene therapy for diseases candidate
(i.e.x-SCID, CGD, WAS,ADA- SCID).43
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Successful treatment of hematological malignancy by HCT is
complicated by the intensity of alloimmune response; too
strong—GVHD, or too weak—relapse. Natural Killer (NK) cell
